1
|
Gondé H, Belaid I, Lamoureux F, Martinet J, Varin R, Tétart F, Hervouët C. Stability Over Time of In-Hospital-Compounded Amoxicillin Capsules and Ceftriaxone Patch Tests for Drug Allergy Testing. J Investig Allergol Clin Immunol 2023; 33:292-294. [PMID: 36193745 DOI: 10.18176/jiaci.0864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/28/2023] Open
Affiliation(s)
- H Gondé
- Department of Pharmacy, Rouen University Hospital, Rouen, France
- Normandie University, UNIROUEN, INSERM U1234, Pathophysiology, Autoimmunity, Neuromuscular Diseases and Regenerative THErapies, Rouen, France
| | - I Belaid
- Department of Pharmacy, Rouen University Hospital, Rouen, France
- Department of Pharmacology and Toxicology, Rouen University Hospital, Rouen, France
| | - F Lamoureux
- Department of Pharmacology and Toxicology, Rouen University Hospital, Rouen, France
| | - J Martinet
- Normandie University, UNIROUEN, INSERM U1234, Pathophysiology, Autoimmunity, Neuromuscular Diseases and Regenerative THErapies, Rouen, France
- Department of Immunology and Biotherapy, Rouen University Hospital, Rouen, France
| | - R Varin
- Department of Pharmacy, Rouen University Hospital, Rouen, France
- Normandie University, UNIROUEN, INSERM U1234, Pathophysiology, Autoimmunity, Neuromuscular Diseases and Regenerative THErapies, Rouen, France
| | - F Tétart
- Department of Allergology, Rouen University Hospital, Centre Erik Satie, Rouen, France
| | - C Hervouët
- Department of Pharmacy, Rouen University Hospital, Rouen, France
| |
Collapse
|
2
|
Griffeuille P, El Balkhi S, Bodeau S, Lamoureux F, Marquet P, Dulaurent S, Saint-Marcoux F. Ultrafast Measurement of Metformin in the Clinical Setting Using Probe Electrospray Ionization Mass Spectrometry. J Anal Toxicol 2023; 47:89-95. [PMID: 35642751 DOI: 10.1093/jat/bkac034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 05/20/2022] [Accepted: 06/01/2022] [Indexed: 11/14/2022] Open
Abstract
Metformin (MtF) is a treatment used for type 2 diabetes. Lactic acidosis (LA) is a frequent complication that can be either induced by or associated with elevated MtF plasma concentrations. When coupled with a mass spectrometry (MS) system, the probe electrospray ionization (PESI) method allows direct and rapid analysis of different types of matrices without pretreatment. In this study, we developed a PESI-MS method for the determination of MtF in plasma. We used a tandem mass spectrometer equipped with a PESI source in the reaction monitoring mode for the quantitation of MtF. MtF-d6 was chosen as the internal standard (IS), following an isotope dilution (ID) approach. The method was fully validated with six concentration levels (0.5-50 mg/L). The matrix effect was evaluated for each level, and the specificity was tested with a mix of potential co-medications. Using patient samples, the performance was compared with two classical LC-MS-MS and LC-diode array detector (DAD) methods used in external labs. Sample preparation consisted in mixing 10 µL plasma in 1,000 µL ethanol/ammonium formate buffer including MtF-d6 at a fixed concentration of 5 mg/L. The total run time was 0.31 min. ID gave satisfactory results of accuracy and precision (min-max: -12.1 to 15.8% and 1.0-17.1%, respectively). The matrix effect was fully corrected by the internal standard (bias < 1%). The specificity study also reported satisfactory results. Finally, in a representative group of 29 patients (55% with a concentration <5 mg/L, 38% with a concentration >5 mg/L and 7% not detected), we observed almost identical results when comparing LC-DAD and LC-MS-MS to PESI-MS (r2 > 0.99). We propose a specific, sensitive, accurate and ultrafast solution for the measurement of MtF in patient plasma, with no sample preparation or calibration curve building. This could be helpful in a core lab when rapid diagnosis of LA is needed.
Collapse
Affiliation(s)
- Pauline Griffeuille
- Department of Pharmacology and Toxicology, Limoges University Hospital, 2 Avenue Martin Luther King, Limoges 87042, France
| | - Souleiman El Balkhi
- Department of Pharmacology and Toxicology, Limoges University Hospital, 2 Avenue Martin Luther King, Limoges 87042, France
| | - Sandra Bodeau
- Department of Pharmacology and Toxicology, Amiens University Hospital, 1 Rond-Point du Professeur Christian Cabrol, Amiens 80054, France
| | - Fabien Lamoureux
- Department of Pharmacology and Toxicology, Rouen University Hospital, 37 Boulevard Gambetta, Rouen 76000, France
| | - Pierre Marquet
- Department of Pharmacology and Toxicology, Limoges University Hospital, 2 Avenue Martin Luther King, Limoges 87042, France.,Pharmacology & Transplantation, UMR1248, INSERM, University of Limoges, Rue du Pr. Bernard Descottes, Limoges 87025, France
| | - Sylvain Dulaurent
- Department of Pharmacology and Toxicology, Limoges University Hospital, 2 Avenue Martin Luther King, Limoges 87042, France
| | - Franck Saint-Marcoux
- Department of Pharmacology and Toxicology, Limoges University Hospital, 2 Avenue Martin Luther King, Limoges 87042, France.,Department of Toxicology, Faculty of Pharmacy, 2 Rue du Dr Marcland, Limoges 87025, France
| |
Collapse
|
3
|
Bourgoin P, Lecomte J, Oualha M, Berthomieu L, Pereira T, Davril E, Lamoureux F, Joram N, Chenouard A, Duflot T. Population Pharmacokinetics of Levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation. Clin Pharmacokinet 2023; 62:335-348. [PMID: 36631687 DOI: 10.1007/s40262-022-01199-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/11/2022] [Indexed: 01/13/2023]
Abstract
BACKGROUND Levosimendan (LVSMD) is a calcium-sensitizer inotropic and vasodilator agent whose use might have a beneficial effect on the weaning of venoarterial extracorporeal membrane oxygenation (VA-ECMO). In light of LVSMD pharmacological characteristics, we hypothesized that ECMO may induce major pharmacokinetic (PK) modifications for LVSMD and its metabolites. OBJECTIVE The aim of this study was to investigate the PK of LVSMD and its metabolites, and to assess the effects of ECMO on PK parameters. METHODS We conducted a multicentric, prospective study (NCT03681379). Twenty-seven infusions of LVSMD were performed, allowing for the collection of 255 blood samples. Non-linear mixed-effects modeling software (MONOLIX®) was used to develop a parent-metabolite PK model of LVSMD and its metabolites. RESULTS Most patients received a 0.2 µg/kg/min infusion of LVSMD over 24 h. After elimination of non-reliable samples or concentrations below the limit of quantification, 166, 101 and 85 samples were considered for LVSMD, OR-1855 and OR-1896, respectively, of which 81, 53 and 41, respectively, were drawn under ECMO conditions. Parent-metabolite PK modeling revealed that a two-compartment model with first-order elimination best described LVSMD PK. Use of a transit compartment allowed for an explanation of the delayed appearance of circulating OR-1855 and OR-1896, with the latter following a first-order elimination. Patient weight influenced the central volume of distribution and elimination of LVSMD. ECMO support increased the elimination rate of LVSMD by 78%, and ECMO also slowed down the metabolite formation rate by 85% for OR-1855, which in turn is converted to the active metabolite OR-1896, 14% slower than without ECMO. Simulated data revealed that standard dosing may not be appropriate for patients under ECMO, with a decrease in the steady-state concentration of LVSMD and lower exposure to the active metabolite OR-1896. CONCLUSIONS ECMO altered PK parameters for LVSMD and its metabolites. An infusion of LVSMD over 48 h, instead of 24 h, with a slightly higher dose may promote synthesis of the active metabolite OR-1896, which is responsible for the long-term efficacy of LVSMD. Further trials evaluating ECMO effects using a PK/pharmacodynamic approach may be of interest. REGISTRATION ClinicalTrials.gov identifier number NCT03681379.
Collapse
Affiliation(s)
- Pierre Bourgoin
- Pediatric Intensive Care Unit, CHU Nantes, 44093, Nantes, France. .,Department of Anesthesiology, CHU Nantes, 44093, Nantes, France.
| | - Jules Lecomte
- Department of Anesthesiology, CHU Nantes, 44093, Nantes, France
| | - Mehdi Oualha
- Pediatric Intensive Care Unit, CHU Necker Enfants Malades, 75015, Paris, France
| | - Lionel Berthomieu
- Pediatric Intensive Care Unit, CHU Toulouse, 31059, Toulouse, France
| | - Tony Pereira
- INSERM U1096, UNIROUEN, Normandie University, 76000, Rouen, France
| | - Emeline Davril
- INSERM U1096, UNIROUEN, Normandie University, 76000, Rouen, France
| | - Fabien Lamoureux
- INSERM U1096, UNIROUEN, Normandie University, 76000, Rouen, France.,Department of Pharmacology, CHU Rouen, 76000, Rouen, France
| | - Nicolas Joram
- Pediatric Intensive Care Unit, CHU Nantes, 44093, Nantes, France
| | - Alexis Chenouard
- Pediatric Intensive Care Unit, CHU Nantes, 44093, Nantes, France
| | - Thomas Duflot
- INSERM U1096, UNIROUEN, Normandie University, 76000, Rouen, France.,Department of Pharmacology, CHU Rouen, 76000, Rouen, France.,CHU Rouen, CIC-CRB U1404, 76000, Rouen, France
| |
Collapse
|
4
|
Bourgoin P, Lecomte J, Oualha M, Berthomieu L, Pereira T, Davril E, Lamoureux F, Joram N, Chenouard A, Duflot T. Correction to: Population Pharmacokinetics of Levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation. Clin Pharmacokinet 2023; 62:349. [PMID: 36752992 DOI: 10.1007/s40262-023-01218-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
- Pierre Bourgoin
- Pediatric Intensive Care Unit, CHU Nantes, 44093, Nantes, France. .,Department of Anesthesiology, CHU Nantes, 44093, Nantes, France.
| | - Jules Lecomte
- Department of Anesthesiology, CHU Nantes, 44093, Nantes, France
| | - Mehdi Oualha
- Pediatric Intensive Care Unit, CHU Necker Enfants Malades, 75015, Paris, France
| | - Lionel Berthomieu
- Pediatric Intensive Care Unit, CHU Toulouse, 31059, Toulouse, France
| | - Tony Pereira
- INSERM U1096, UNIROUEN, Normandie University, 76000, Rouen, France
| | - Emeline Davril
- INSERM U1096, UNIROUEN, Normandie University, 76000, Rouen, France
| | - Fabien Lamoureux
- INSERM U1096, UNIROUEN, Normandie University, 76000, Rouen, France.,Department of Pharmacology, CHU Rouen, 76000, Rouen, France
| | - Nicolas Joram
- Pediatric Intensive Care Unit, CHU Nantes, 44093, Nantes, France
| | - Alexis Chenouard
- Pediatric Intensive Care Unit, CHU Nantes, 44093, Nantes, France
| | - Thomas Duflot
- INSERM U1096, UNIROUEN, Normandie University, 76000, Rouen, France.,Department of Pharmacology, CHU Rouen, 76000, Rouen, France.,CHU Rouen, CIC-CRB U1404, 76000, Rouen, France
| |
Collapse
|
5
|
Cavelier M, Gondé H, Costa D, Lamoureux F, Pereira T, Buchbinder N, Varin R, Hervouët C. Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension. Pharmaceutics 2023; 15:pharmaceutics15020446. [PMID: 36839767 PMCID: PMC9963445 DOI: 10.3390/pharmaceutics15020446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 01/20/2023] [Accepted: 01/27/2023] [Indexed: 01/31/2023] Open
Abstract
Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their composition may undergo substantial modifications. The aim of this study was to propose a new oral formulation of nicardipine hydrochloride 2 mg/mL using simple excipients. The formulation included hydroxypropylmethylcellulose, simple syrup, polysorbate 80, sodium saccharin, citrate buffer, strawberry flavor and 0.2% potassium sorbate. The uniformity of content was maintained before and after agitation. Nicardipine hydrochloride concentration assessed by HPLC-MS/MS remained above 90% for 365 days before opening and for 28 days after opening. pH and osmolality were maintained throughout the study, and no microbial contamination was observed. The uniformity of mass of the delivered doses was evaluated using four different devices. A new oral formulation of nicardipine hydrochloride 2 mg/mL was developed using simple and safe excipients. Pharmacological and clinical parameters remain to be assessed and compared with those of the previous formulation.
Collapse
Affiliation(s)
- Marine Cavelier
- CHU Rouen, Department of Pharmacy, F-76000 Rouen, France
- Correspondence:
| | - Henri Gondé
- CHU Rouen, Department of Pharmacy, Normandie University, UNIROUEN, U1234, F-76000 Rouen, France
| | - Damien Costa
- CHU Rouen, Department of Parasitology-Mycology, Normandie University, UNIROUEN, EA7510 ESCAPE, F-76000 Rouen, France
| | | | - Tony Pereira
- CHU Rouen, Department of Pharmacology, F-76000 Rouen, France
| | - Nimrod Buchbinder
- CHU Rouen, Department of Pediatric Oncology and Hematology, F-76000 Rouen, France
| | - Rémi Varin
- CHU Rouen, Department of Pharmacy, Normandie University, UNIROUEN, U1234, F-76000 Rouen, France
| | | |
Collapse
|
6
|
Giry M, Sarfati S, Pestel-Caron M, Wils J, Lamoureux F, Alexandre K. Comment on: Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae. J Antimicrob Chemother 2022; 77:2892-2894. [PMID: 35538913 DOI: 10.1093/jac/dkac150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Affiliation(s)
- Marion Giry
- Normandie Univ, UNIROUEN, INSERM U1311 DYNAMICURE, F-76000 Rouen, France
| | - Sacha Sarfati
- CHU Rouen, Department of Pharmacology - Toxicology and Pharmacogenetics, F-76000 Rouen, France
| | - Martine Pestel-Caron
- Normandie Univ, UNIROUEN, INSERM U1311 DYNAMICURE, F-76000 Rouen, France.,Normandie Univ, UNIROUEN, UNICAEN, INSERM U1311 DYNAMICURE, CHU Rouen, Department of Microbiology, F-76000 Rouen, France
| | - Julien Wils
- CHU Rouen, Department of Pharmacology - Toxicology and Pharmacogenetics, F-76000 Rouen, France
| | - Fabien Lamoureux
- CHU Rouen, Department of Pharmacology - Toxicology and Pharmacogenetics, F-76000 Rouen, France
| | - Kévin Alexandre
- Normandie Univ, UNIROUEN, INSERM U1311 DYNAMICURE, F-76000 Rouen, France.,Normandie Univ, UNIROUEN, UNICAEN, INSERM U1311 DYNAMICURE, CHU Rouen, Department of infectious diseases, F-76000 Rouen, France
| |
Collapse
|
7
|
Mossé U, Chaumette B, Wils J, Imbert L, Lamoureux F, Ferrafiat V. Evidence of pharmacogenetics-based fluvoxamine use as an add-on to clozapine treatment in psychiatry. Pharmacogenomics 2022; 23:649-654. [PMID: 35916148 DOI: 10.2217/pgs-2022-0007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Pharmacological treatments used for psychiatric disorders, such as clozapine, demonstrate large interindividual variability in terms of possible adverse effects and therapeutic benefit. This variability can be explained by multiple factors, including pharmacogenetic factors. Clozapine efficacy can be impacted by CYP polymorphisms. A growing body of literature on pharmacogenetics suggests the clinical benefit of concomitant use of clozapine and fluvoxamine to improve global pharmacotherapeutic management. This article reviews and discusses available clinical and pharmacological data and limitations of clozapine augmentation with fluvoxamine based on pharmacogenetic rationale and clinical experience. The aim is to provide an updated approach on how to use the pharmacological and pharmacogenetic profile to improve clozapine efficacy and tolerance in severely ill patients.
Collapse
Affiliation(s)
- Ulysse Mossé
- Child and Adolescent Psychiatric Unit, L'Unité Régionale d'Hospitalisation Psychiatrique pour Enfants et Adolescents, Centre Hospitalier du Rouvray Sotteville-les Rouen, Rouen, 76000, France
| | - Boris Chaumette
- Institut National de la Santé et de la Recherche Médicale U1266, Institute of Psychiatry and Neuroscience of Paris, Paris, 75000, France.,Groupe Hospitalier Universitaire Paris, Psychiatrie et Neurosciences, Paris, 75000, France.,Department of Psychiatry, McGill University, Montreal, H3A 0G4, Canada
| | - Julien Wils
- Department of Pharmacology, Toxicology and Pharmacogenetics, Rouen University Hospital, Rouen, 76000, France.,Institut National de la Santé et de la Recherche Médicale U1096, Université de Rouen Normandie, Rouen, 76000, France
| | - Laurent Imbert
- Department of Pharmacology, Toxicology and Pharmacogenetics, Rouen University Hospital, Rouen, 76000, France
| | - Fabien Lamoureux
- Department of Pharmacology, Toxicology and Pharmacogenetics, Rouen University Hospital, Rouen, 76000, France.,Institut National de la Santé et de la Recherche Médicale U1096, Université de Rouen Normandie, Rouen, 76000, France
| | - Vladimir Ferrafiat
- Intensive Care Unit, Department of Child and Adolescent Psychiatry, Marseille-Nord University Hospital, Marseille, 13000, France.,Reference Center for Inborn Errors of Metabolism, La Timone University Hospital, Assistance Publique - Hopitaux de Marseille, Marseille, 13000, France
| |
Collapse
|
8
|
Imbert L, Lagoutte-Renosi J, Wils J, Lamoureux F. Proposals for a standardized procedure of validation of DNA extraction and allelic discrimination assays in pharmacogenomics according to ISO15189 requirements. Pharmacogenet Genomics 2022; 32:192-200. [PMID: 35503003 DOI: 10.1097/fpc.0000000000000473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES In the era of quality management in clinical laboratories, method validation can be a challenge without appropriate guidelines, such as in the field of pharmacogenetics. The present work describes a method validation for DNA extraction and CYP3A5*3 genotyping, which would meet ISO15189:2012 requirements. METHODS DNA extraction was performed using a QIAamp DSP DNA Blood kit, DNA purity and concentration were determined using a Nanodrop, and the genotyping assay was a real-rime PCR using TaqMan reagents. Validation criteria were similar to those usually verified when validating methods in the analytical field: specificity, sensitivity, cross-over contamination, stability of reagents, robustness, lower and upper limits of detection, and between-run and within-run precisions. A comparison to alternate or reference methods was also performed (i.e. QiAamp kit versus DNA extractor and TaqMan genotyping versus Sanger sequencing). Each validation step is described from the pharmacogenetic point of view, as well as acceptance criteria for both DNA extraction [i.e. concentration relative SD (RSD) below 25%, verified purity, and no DNA in blank samples] and genotyping assay (i.e. specificity and diagnostic sensitivity, RSD of mean threshold cycle below 15%, no amplification in blank samples). RESULTS Concerning CYP3A5 genotyping following a DNA extraction described as an example, validation criteria were met, allowing routine use of this analytical process. Cost estimation of the overall validation procedure was approximately 290 euros, concerning reagents and consumables. CONCLUSION This work aims to provide a reference for method validation for pharmacogenetic analysis using real-time PCR to detect single nucleotide polymorphisms, in accordance with ISO15189:2012.
Collapse
Affiliation(s)
- Laurent Imbert
- Pharmacology Department, Laboratory of Pharmacology, Toxicology and Pharmacogenetic, Rouen University Hospital
- Normandie University, UNIROUEN, INSERM U1096, Rouen
| | - Jennifer Lagoutte-Renosi
- Pharmacology Department, Laboratory of Pharmacology, Toxicology and Pharmacogenetic, Rouen University Hospital
- Current affiliation: EA 3920 Université Bourgogne Franche-Comté, F-25000 Besançon, France; Laboratoire de Pharmacologie Clinique et Toxicologie-CHU de Besançon, Besançon, France
| | - Julien Wils
- Pharmacology Department, Laboratory of Pharmacology, Toxicology and Pharmacogenetic, Rouen University Hospital
- Normandie University, UNIROUEN, INSERM U1096, Rouen
| | - Fabien Lamoureux
- Pharmacology Department, Laboratory of Pharmacology, Toxicology and Pharmacogenetic, Rouen University Hospital
- Normandie University, UNIROUEN, INSERM U1096, Rouen
| |
Collapse
|
9
|
Scherrer V, Lamoureux F, Chaventre C, Thill C, Demailly Z, Selim J, Bauer F, Imbert L, Wurtz V, Compère V, Clavier T, Besnier E. Reliability of the Minto model for target-controlled infusion of remifentanil during cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2022; 129:163-171. [PMID: 35750514 DOI: 10.1016/j.bja.2022.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 05/03/2022] [Accepted: 05/06/2022] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND The Minto pharmacokinetic model is used for target-controlled infusion of remifentanil. The reliability of this model has never been evaluated during normothermic cardiac surgery with cardiopulmonary bypass (CPB). The aim of this study was to assess the predictive performance of the model during CPB to determine its reliability during cardiac surgery. METHODS This was a single-centre observational study. Arterial blood samples were drawn at five time points: T1, after tracheal intubation; T2, immediately before CPB; T3, 10 min after starting CPB; T4, 45 min after starting CPB; T5, 10 min after weaning off CPB. Prediction error (PE) and absolute prediction error (APE) were calculated for each sample and used to determine median prediction error (MDPE) and median absolute prediction error (MDAPE) per patient. Risk factors for APE >30% were assessed using multivariable analysis. Results are presented as medians with inter-quartile ranges. RESULTS Fifty-eight patients with 283 blood samples (110 during CPB) were included. In the pre-CPB period, MDPE and MDAPE were -17.3 [-32.9 to 2.3] and 24.6 [12-37.7]%, whereas during CPB, they were -1.8 [-15.6 to 11.1] and 14.0 [6.74-27.1]%, respectively. There was no statistically significant difference between measured and predicted remifentanil plasma concentrations during CPB. Age, preoperative albumin concentrations, temperature, and haemodilution were not independently associated with MDAPE >30%. CONCLUSIONS The Minto model accurately predicts plasma remifentanil concentrations during cardiac surgery with CPB. CLINICAL TRIAL REGISTRATION 2017-A03153-50.
Collapse
Affiliation(s)
- Vincent Scherrer
- Rouen University Hospital, Department of Anaesthesiology and Critical Care, Rouen, France
| | - Fabien Lamoureux
- Rouen University Hospital, Department of Pharmacology, Rouen, France; Normandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen, France
| | - Céline Chaventre
- Rouen University Hospital, Department of Anaesthesiology and Critical Care, Rouen, France
| | - Caroline Thill
- Rouen University Hospital, Department of Biostatistics, Rouen, France
| | - Zoe Demailly
- Rouen University Hospital, Department of Anaesthesiology and Critical Care, Rouen, France; Normandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen, France
| | - Jean Selim
- Rouen University Hospital, Department of Anaesthesiology and Critical Care, Rouen, France; Normandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen, France
| | - Fabrice Bauer
- Normandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen, France; Rouen University Hospital, Department of Cardiac Surgery, Rouen, France
| | - Laurent Imbert
- Rouen University Hospital, Department of Pharmacology, Rouen, France
| | - Véronique Wurtz
- Rouen University Hospital, Department of Anaesthesiology and Critical Care, Rouen, France
| | - Vincent Compère
- Rouen University Hospital, Department of Anaesthesiology and Critical Care, Rouen, France; Normandie Univ, UNIROUEN, INSERM U1239, Rouen, France
| | - Thomas Clavier
- Rouen University Hospital, Department of Anaesthesiology and Critical Care, Rouen, France; Normandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen, France
| | - Emmanuel Besnier
- Rouen University Hospital, Department of Anaesthesiology and Critical Care, Rouen, France; Normandie Univ, UNIROUEN, Inserm U1096, EnVi, Rouen, France.
| |
Collapse
|
10
|
Tron C, Bouvet R, Verdier MC, Lamoureux F, Hennart B, Dubourg C, Bellissant E, Galibert MD. A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes. Pharmaceuticals (Basel) 2022; 15:ph15050637. [PMID: 35631462 PMCID: PMC9145594 DOI: 10.3390/ph15050637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 05/11/2022] [Accepted: 05/13/2022] [Indexed: 11/16/2022] Open
Abstract
In the field of pharmacogenetics, the trend is to analyze a panel of several actionable genetic polymorphisms. It may require the use of high-throughput sequencing which demands expensive reagents/instruments and specific skills to interpret results. As an alternative, the aim of this work was to validate an easy, fast, and inexpensive multiplex pharmacogenetics assay to simultaneously genotype a panel of 17 clinically actionable variants involved in drug pharmacokinetics/pharmacodynamics. We designed primers to perform a multiplex PCR assay using a single mix. Primers were labeled by two fluorescent dye markers to discriminate alleles, while the size of the PCR fragments analyzed by electrophoresis allowed identifying amplicon. Polymorphisms of interest were CYP3A4*22, CYP3A5*3, CYP1A2*1F, CYP2C9*2-*3, CYP2C19*2-*3-*17, VKORC1-1639G > A, ABCB1 rs1045642-rs1128503-rs2229109-rs2032582, and CYP2D6*3-*4-*6-*9. The assay was repeatable and a minimum quantity of 10 ng of DNA/ sample was needed to obtain accurate results. The method was applied to a validation cohort of 121 samples and genotyping results were consistent with those obtained with reference methods. The assay was fast and cost-effective with results being available within one working-day. This robust assay can easily be implemented in laboratories as an alternative to cumbersome simplex assays or expensive multiplex approaches. Together it should widespread access to pharmacogenetics in clinical routine practice.
Collapse
Affiliation(s)
- Camille Tron
- Pharmacology Department, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Univ Rennes, F-35000 Rennes, France; (M.-C.V.); (E.B.)
- Correspondence: ; Tel.: +33-2-99-28-42-80
| | - Régis Bouvet
- Department of Molecular Genetics and Genomics, Rennes Hospital University, F-35000 Rennes, France; (R.B.); (C.D.); (M.-D.G.)
| | - Marie-Clémence Verdier
- Pharmacology Department, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Univ Rennes, F-35000 Rennes, France; (M.-C.V.); (E.B.)
| | | | - Benjamin Hennart
- CHU Lille, Service de Toxicologie et Génopathies, F-59000 Lille, France;
| | - Christèle Dubourg
- Department of Molecular Genetics and Genomics, Rennes Hospital University, F-35000 Rennes, France; (R.B.); (C.D.); (M.-D.G.)
- CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, Univ Rennes, F-35000 Rennes, France
| | - Eric Bellissant
- Pharmacology Department, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Univ Rennes, F-35000 Rennes, France; (M.-C.V.); (E.B.)
| | - Marie-Dominique Galibert
- Department of Molecular Genetics and Genomics, Rennes Hospital University, F-35000 Rennes, France; (R.B.); (C.D.); (M.-D.G.)
- CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, Univ Rennes, F-35000 Rennes, France
| |
Collapse
|
11
|
Duflot T, Pereira T, Tavolacci M, Joannidès R, Aubrun F, Lamoureux F, Lvovschi VE. Pharmacokinetic modeling of morphine and its glucuronides: Comparison of nebulization versus intravenous route in healthy volunteers. CPT Pharmacometrics Syst Pharmacol 2022; 11:82-93. [PMID: 34842366 PMCID: PMC8752103 DOI: 10.1002/psp4.12735] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 09/23/2021] [Accepted: 09/28/2021] [Indexed: 01/17/2023] Open
Affiliation(s)
- Thomas Duflot
- Normandie Univ, UNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology Rouen France
| | - Tony Pereira
- CHU Rouen, Department of Pharmacology Rouen France
| | | | - Robinson Joannidès
- Normandie Univ, UNIROUEN, INSERM U1096, CHU Rouen, Department of Pharmacology Rouen France
| | - Frédéric Aubrun
- Department of Anaesthesia and Intensive Care Medicine, Croix Rousse Hospital Claude Bernard University Lyon 1 Lyon France
| | - Fabien Lamoureux
- Normandie Univ, UNIROUEN, INSERM U1096, CHU Rouen, Laboratory of Pharmacology – Toxicology and Pharmacogenetics Rouen France
| | | |
Collapse
|
12
|
Imbert L, Duflot T, Vasse M, Guillerme J, Djerada Z, Goetz H, Wils J, Lamoureux F. Suivi toxicocinétique des cannabinoïdes urinaires rapportés à la créatinine dans le cadre du sevrage de consommateurs chroniques suivis en psychiatrie. Toxicologie Analytique et Clinique 2021. [DOI: 10.1016/j.toxac.2021.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Fuss D, Gondé H, Lamoureux F, Pereira T, Colnot M, Buchbinder N, Coquard A, Varin R, Hervouët C. Stability study of a compounded oral solution of nicardipine for the treatment of hypertension in children. Eur J Pharm Sci 2021; 160:105738. [PMID: 33524504 DOI: 10.1016/j.ejps.2021.105738] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 12/19/2020] [Accepted: 01/25/2021] [Indexed: 11/18/2022]
Abstract
Nicardipine is an antihypertensive drug that may be used off-label by oral route to treat hypertension in children. Currently commercially available tablets are inappropriate for oral use in children and manufactured hard capsules are not suitable for easy dose individualization to achieve target blood pressure. We aimed to fulfill this lack of appropriate dose forms by developing an oral liquid formulation of nicardipine. We compounded an extemporaneous 2 mg/mL nicardipine solution in InOrpha® vehicle for oral use with 1% polysorbate 80. A HPLC-MS/MS stability-indicating method was developed and validated. The stability was assessed under room temperature and refrigerated storage conditions. Nicardipine concentration remained above 95% of the initial concentration for 90 days in both storage conditions, without apparition of degradation products. Organoleptic parameters, pH, osmolality, viscosity and density were assessed and remained stable throughout storage. A uniformity of content was maintained before and after agitation of the packaging bottles. Mass uniformity of delivered doses was also ensured. Finally, the formulation met the Pharmacopoeia specifications for microbiological contaminations. In this study we report a compounded formulation of nicardipine for oral use in pediatrics. This solution, which could be easily manufactured, is being used in our hospital. Pharmacological and clinical parameters including bioavailability, pharmacokinetics, efficacy and tolerance remain to be assessed.
Collapse
Affiliation(s)
- Damien Fuss
- Rouen University Hospital, Department of Pharmacy, F 76000 Rouen, France
| | - Henri Gondé
- Normandie Univ, UNIROUEN, U1234, Rouen University Hospital, Department of Pharmacy, F 76000, Rouen, France.
| | - Fabien Lamoureux
- Rouen University Hospital, Department of Pharmacology, F 76000 Rouen, France
| | - Tony Pereira
- Rouen University Hospital, Department of Pharmacology, F 76000 Rouen, France
| | - Marion Colnot
- Rouen University Hospital, Department of Pharmacy, F 76000 Rouen, France
| | - Nimrod Buchbinder
- Rouen University Hospital, Department of Pediatric Oncology and Hematology, F 76000 Rouen, France
| | - Aude Coquard
- Rouen University Hospital, Department of Pharmacy, F 76000 Rouen, France
| | - Rémi Varin
- Normandie Univ, UNIROUEN, U1234, Rouen University Hospital, Department of Pharmacy, F 76000, Rouen, France
| | - Charles Hervouët
- Rouen University Hospital, Department of Pharmacy, F 76000 Rouen, France
| |
Collapse
|
14
|
Duflot T, Laurent C, Soudey A, Fonrose X, Hamzaoui M, Iacob M, Bertrand D, Favre J, Etienne I, Roche C, Coquerel D, Le Besnerais M, Louhichi S, Tarlet T, Li D, Brunel V, Morisseau C, Richard V, Joannidès R, Stanke-Labesque F, Lamoureux F, Guerrot D, Bellien J. Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients. Sci Rep 2021; 11:3739. [PMID: 33580125 PMCID: PMC7881112 DOI: 10.1038/s41598-021-83274-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 01/27/2021] [Indexed: 12/25/2022] Open
Abstract
This study addressed the hypothesis that epoxyeicosatrienoic acids (EETs) synthesized by CYP450 and catabolized by soluble epoxide hydrolase (sEH) are involved in the maintenance of renal allograft function, either directly or through modulation of cardiovascular function. The impact of single nucleotide polymorphisms (SNPs) in the sEH gene EPHX2 and CYP450 on renal and vascular function, plasma levels of EETs and peripheral blood monuclear cell sEH activity was assessed in 79 kidney transplant recipients explored at least one year after transplantation. Additional experiments in a mouse model mimicking the ischemia–reperfusion (I/R) injury suffered by the transplanted kidney evaluated the cardiovascular and renal effects of the sEH inhibitor t-AUCB administered in drinking water (10 mg/l) during 28 days after surgery. There was a long-term protective effect of the sEH SNP rs6558004, which increased EET plasma levels, on renal allograft function and a deleterious effect of K55R, which increased sEH activity. Surprisingly, the loss-of-function CYP2C9*3 was associated with a better renal function without affecting EET levels. R287Q SNP, which decreased sEH activity, was protective against vascular dysfunction while CYP2C8*3 and 2C9*2 loss-of-function SNP, altered endothelial function by reducing flow-induced EET release. In I/R mice, sEH inhibition reduced kidney lesions, prevented cardiac fibrosis and dysfunction as well as preserved endothelial function. The preservation of EET bioavailability may prevent allograft dysfunction and improve cardiovascular disease in kidney transplant recipients. Inhibition of sEH appears thus as a novel therapeutic option but its impact on other epoxyfatty acids should be carefully evaluated.
Collapse
Affiliation(s)
- Thomas Duflot
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Laboratory of Pharmacokinetics, Toxicology and Pharmacogenetics, Rouen University Hospital, 76000, Rouen, France
| | - Charlotte Laurent
- Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Anne Soudey
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Xavier Fonrose
- Department of Pharmacology, Grenoble Alpes University Hospital, HP2, INSERM U1042, University of Grenoble Alpes, 38000, Grenoble, France
| | - Mouad Hamzaoui
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Michèle Iacob
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France
| | - Dominique Bertrand
- Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Julie Favre
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Isabelle Etienne
- Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Clothilde Roche
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - David Coquerel
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Maëlle Le Besnerais
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Safa Louhichi
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Tracy Tarlet
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Dongyang Li
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA, 95616, USA
| | - Valéry Brunel
- Department of General Biochemistry, Rouen University Hospital, 76000, Rouen, France
| | - Christophe Morisseau
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA, 95616, USA
| | - Vincent Richard
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France
| | - Robinson Joannidès
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Centre d'Investigation Clinique (CIC)-INSERM 1404, Rouen University Hospital, 76000, Rouen, France
| | - Françoise Stanke-Labesque
- Department of Pharmacology, Grenoble Alpes University Hospital, HP2, INSERM U1042, University of Grenoble Alpes, 38000, Grenoble, France
| | - Fabien Lamoureux
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France.,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Laboratory of Pharmacokinetics, Toxicology and Pharmacogenetics, Rouen University Hospital, 76000, Rouen, France
| | - Dominique Guerrot
- UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France.,Department of Nephrology, Rouen University Hospital, 76000, Rouen, France
| | - Jérémy Bellien
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen, France. .,UNIROUEN, INSERM U1096, FHU CARNAVAL, Normandie University, 76000, Rouen, France. .,Centre d'Investigation Clinique (CIC)-INSERM 1404, Rouen University Hospital, 76000, Rouen, France. .,Department of Pharmacology, Rouen University Hospital, 76031, Rouen Cedex, France.
| |
Collapse
|
15
|
Berel C, Mossé U, Wils J, Cousin L, Imbert L, Gerardin P, Chaumette B, Lamoureux F, Ferrafiat V. Interest of Fluvoxamine as an Add-On to Clozapine in Children With Severe Psychiatric Disorder According to CYP Polymorphisms: Experience From a Case Series. Front Psychiatry 2021; 12:669446. [PMID: 34234701 PMCID: PMC8255476 DOI: 10.3389/fpsyt.2021.669446] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 05/21/2021] [Indexed: 01/24/2023] Open
Abstract
Despite its drastic efficacy in resistant psychiatric disorders, clozapine remains rarely used in youth due to its side effects. Clozapine plasma level is determined through its metabolism involving several isoforms of cytochromes 450 (CYP450) family. Isoform CYP1A2 appears as a limiting enzyme involved in the metabolism of clozapine, while isoforms 2C19, 2D6, 3A4, and 3A5 also contribute in a minor way. Clozapine efficacy is limited by a significant inter-patient variability in exposure according to CYP's polymorphisms. Clozapine plasma levels may be increased with CYP inhibitors such as fluvoxamine. This drug is a potent enzymatic inhibitor of CYP1A2 and, to a lesser extent, of CYP3A4 and CYP2D6. Hence, in case of CYP's polymorphisms in youth, the use of fluvoxamine as add-on to clozapine could help in reaching clinical and biological efficacy and allowing lower clozapine dosage and a better tolerance profile as it has already been described in adults. We report four pediatric cases with severe psychiatric disorders underlying our experience with CYP polymorphism explorations and the use of fluvoxamine as add-on to clozapine. Our four patients clinically improved after the introduction of fluvoxamine, enhancing clozapine metabolism and therefore the clozapine plasma level within therapeutic range. Despite the interesting results of fluvoxamine, we report a severe issue of tolerance for one patient, emphasizing the need for caution regarding possible drug interactions when fluvoxamine is considered. Hence, we propose a detailed step-by-step multidisciplinary protocol.
Collapse
Affiliation(s)
- Camille Berel
- Child and Adolescent Psychiatric Unit, URHEA, CHSR Sotteville les Rouen, Sotteville les Rouen, France
| | - Ulysse Mossé
- Child and Adolescent Psychiatric Unit, URHEA, CHSR Sotteville les Rouen, Sotteville les Rouen, France
| | - Julien Wils
- Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen University Hospital, Rouen, France.,Normandie Univ, UNIROUEN, Inserm U1096, Rouen, France
| | - Lauriane Cousin
- Child and Adolescent Psychiatric Department, CHRU Lille, Lille, France
| | - Laurent Imbert
- Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen University Hospital, Rouen, France
| | - Priscille Gerardin
- Child and Adolescent Psychiatric Unit, URHEA, CHSR Sotteville les Rouen, Sotteville les Rouen, France.,Child and Adolescent Psychiatric Department, CHU Charles Nicolle, Rouen, France
| | - Boris Chaumette
- Institut de Psychiatrie et Neurosciences de Paris, INSERM UMR 1266, Université de Paris, GDR3557-Institut de Psychiatrie, Paris, France.,GHU Paris Psychiatrie et Neurosciences, Paris, France.,Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - Fabien Lamoureux
- Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen University Hospital, Rouen, France.,Normandie Univ, UNIROUEN, Inserm U1096, Rouen, France
| | - Vladimir Ferrafiat
- Child and Adolescent Psychiatric Unit, URHEA, CHSR Sotteville les Rouen, Sotteville les Rouen, France.,Child and Adolescent Psychiatric Department, CHU Charles Nicolle, Rouen, France
| |
Collapse
|
16
|
Soares A, Alexandre K, Lamoureux F, Lemée L, Caron F, Pestel-Caron M, Etienne M. Efficacy of a ciprofloxacin/amikacin combination against planktonic and biofilm cultures of susceptible and low-level resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2020; 74:3252-3259. [PMID: 31424553 DOI: 10.1093/jac/dkz355] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Revised: 06/21/2019] [Accepted: 07/17/2019] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Eradicating bacterial biofilm without mechanical dispersion remains a challenge. Combination therapy has been suggested as a suitable strategy to eradicate biofilm. OBJECTIVES To evaluate the efficacy of a ciprofloxacin/amikacin combination in a model of in vitro Pseudomonas aeruginosa biofilm. METHODS The antibacterial activity of ciprofloxacin and amikacin (alone, in combination and successively) was evaluated by planktonic and biofilm time-kill assays against five P. aeruginosa strains: PAO1, a WT clinical strain and three clinical strains overexpressing the efflux pumps MexAB-OprM (AB), MexXY-OprM (XY) and MexCD-OprJ (CD), respectively. Amikacin MIC was 16 mg/L for XY and ciprofloxacin MIC was 0.5 mg/L for CD. The other strains were fully susceptible to ciprofloxacin and amikacin. The numbers of total and resistant cells were determined. RESULTS In planktonic cultures, regrowth of high-level resistant mutants was observed when CD was exposed to ciprofloxacin alone and XY to amikacin alone. Eradication was obtained with ciprofloxacin or amikacin in the other strains, or with the combination in XY and CD strains. In biofilm, bactericidal reduction after 8 h followed by a mean 4 log10 cfu/mL plateau in all strains and for all regimens was noticed. No regrowth of resistant mutants was observed whatever the antibiotic regimen. The bacterial reduction obtained with a second antibiotic used simultaneously or consecutively was not significant. CONCLUSIONS The ciprofloxacin/amikacin combination prevented the emergence of resistant mutants in low-level resistant strains in planktonic cultures. Biofilm persister cells were not eradicated, either with monotherapy or with the combination.
Collapse
Affiliation(s)
- Anaïs Soares
- EA 2656 (GRAM), Normandie Univ, Unirouen, Rouen, France.,Microbiology Department, Rouen University Hospital, Rouen, France
| | - Kévin Alexandre
- EA 2656 (GRAM), Normandie Univ, Unirouen, Rouen, France.,Infectious Diseases Department, Rouen University Hospital, Rouen, France
| | - Fabien Lamoureux
- Laboratory of Pharmacology, Toxicology and Pharmacogenetics, Rouen University Hospital, Rouen, France
| | - Ludovic Lemée
- EA 2656 (GRAM), Normandie Univ, Unirouen, Rouen, France.,Microbiology Department, Rouen University Hospital, Rouen, France
| | - François Caron
- EA 2656 (GRAM), Normandie Univ, Unirouen, Rouen, France.,Infectious Diseases Department, Rouen University Hospital, Rouen, France
| | - Martine Pestel-Caron
- EA 2656 (GRAM), Normandie Univ, Unirouen, Rouen, France.,Microbiology Department, Rouen University Hospital, Rouen, France
| | - Manuel Etienne
- EA 2656 (GRAM), Normandie Univ, Unirouen, Rouen, France.,Infectious Diseases Department, Rouen University Hospital, Rouen, France
| |
Collapse
|
17
|
Gueudry J, Le Goff L, Lamoureux F, Pereira T, Levefre S, Razakandrainibe R, Costa D, Ballet JJ, Muraine M, Favennec L. Corneal Pharmacokinetics of Voriconazole and Posaconazole following Intrastromal Injection and Posaconazole Eye Drops Instillation in Rats. Curr Eye Res 2020; 45:1369-1372. [PMID: 32228098 DOI: 10.1080/02713683.2020.1749669] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Purpose/Aims: Infectious keratitis is a major cause of visual impairment and blindness worldwide. Common difficulties in treating fungal keratitis prompt new therapeutic possibilities. In this study, intrastromal voriconazole and posaconazole, and topical posaconazole were tested for their potential to obtain therapeutic cornea concentrations. Materials and Methods: Pharmacokinetics of triazole intracorneal/eye drop administration was studied in rats. Sixty-two rats were treated either by voriconazole or posaconazole. Twenty-nine and 33 rats received intrastromal injection of voriconazole solution (1 μl, 10 mg/ml) and posaconazole solution (1 μl, 18 mg/ml), respectively, administered under microscopic examination with a 32 gauge needle in the left cornea. Posaconazole (1.8% solution) eye drops were used. Cornea and plasma concentrations were determined using 2D HPLC separation and tandem MS, at 30 min, 3 h, 6 h, 24 h, 48 h, 72 h, and 144 h (6 days) post-intrastromal injection. The entire rat cornea was used for chromatography analyses. Results: In anesthetized rats, single intracorneal injection resulted, after 30 min, in respectively, >300 ng/mg and >260 ng/mg cornea concentrations, dropping to low levels within hours, while staying low in plasma. The effect of hourly posaconazole eye drops resulted in >10 ng/mg cornea concentration, which was maintained with instillations every 2 and then every 4 h. Conclusion: Our results show that there is little interest of intrastromal triazole administration due to the short duration of high cornea concentrations obtained after intracorneal injection. Posaconazole eye drops maintain therapeutic cornea concentrations in rats and could be used to treat severe infectious keratitis.
Collapse
Affiliation(s)
- Julie Gueudry
- EA7510 "Epidémio-surveillance Et Circulation Des Parasites Dans L'environnement", University of Rouen Normandie , Rouen, France.,Department of Ophthalmology, Charles Nicolle University Hospital , Rouen, France
| | - Laetitia Le Goff
- EA7510 "Epidémio-surveillance Et Circulation Des Parasites Dans L'environnement", University of Rouen Normandie , Rouen, France
| | - Fabien Lamoureux
- Department of Clinical Pharmacology, Charles Nicolle University Hospital , Rouen, France
| | - Tony Pereira
- Department of Clinical Pharmacology, Charles Nicolle University Hospital , Rouen, France
| | - Sabine Levefre
- Department of Ophthalmology, Charles Nicolle University Hospital , Rouen, France
| | - Romy Razakandrainibe
- EA7510 "Epidémio-surveillance Et Circulation Des Parasites Dans L'environnement", University of Rouen Normandie , Rouen, France
| | - Damien Costa
- EA7510 "Epidémio-surveillance Et Circulation Des Parasites Dans L'environnement", University of Rouen Normandie , Rouen, France
| | - Jean Jacques Ballet
- EA7510 "Epidémio-surveillance Et Circulation Des Parasites Dans L'environnement", University of Rouen Normandie , Rouen, France
| | - Marc Muraine
- Department of Ophthalmology, Charles Nicolle University Hospital , Rouen, France
| | - Loïc Favennec
- EA7510 "Epidémio-surveillance Et Circulation Des Parasites Dans L'environnement", University of Rouen Normandie , Rouen, France
| |
Collapse
|
18
|
Fontanilles M, Fontanilles A, Massy N, Rouvet J, Pereira T, Alexandru C, Hanzen C, Basuyau F, Langlois O, Clatot F, Tennevet I, Di Fiore F, Joannidès R, Lamoureux F. Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. Fundam Clin Pharmacol 2020; 34:484-494. [PMID: 31994757 DOI: 10.1111/fcp.12539] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Revised: 12/24/2019] [Accepted: 01/24/2020] [Indexed: 11/30/2022]
Abstract
Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma. We aimed to compare early platelet concentration kinetics, hematological safety profile, and impact on survival following the initiation of either the brand-name or a generic TMZ formulation. A retrospective trial was conducted in patients suffering from newly diagnosed glioblastoma. Patients were treated with TMZ at 75 mg/m2 per day during six weeks, concomitantly with radiotherapy. Platelet concentration was collected each week. Primary endpoint was to perform a linear mixed-effect model of platelet concentration kinetic over weeks. A total of 147 patients were included as follows: 96 received the brand-name TMZ, and 51 received a generic TMZ formulation. Exposition to the generic was a significant variable that negatively influenced the platelet kinetics in the radiotherapy and concomitant TMZ phase, P = 0.02. Grade ≥3 chemo-induced thrombocytopenia was more frequent in the generic group: 19.6% [95% CI 8.7-30.5%] vs 3.1% [0-6.6%], P = 0.001. Exposition to the generic formulation of TMZ led to increase early treatment discontinuation due to TMZ-induced thrombocytopenia and was a worsening independent prognostic factor on overall survival: adjusted HR 1.83 [1.21-2.8], P = 0.031. These data suggest that exposition to a generic formulation of TMZ vs the brand-name product is associated with higher early platelet decrease leading to clinically relevant impacts on treatment schedule in glioblastoma. Further prospective trials are needed to confirm these results.
Collapse
Affiliation(s)
- Maxime Fontanilles
- UNIROUEN, Inserm U1245, IRON group, Institute for Research and Innovation in Biomedicine, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, Normandie Univ, F-76031, Rouen, France.,Department of Medical Oncology, Cancer Centre Henri Becquerel, F-76000, Rouen, France.,Department of Pharmacology, Rouen University Hospital, F-76031, Rouen, France
| | - Adeline Fontanilles
- Institut supérieur d'agriculture Rhône-Alpes, ISARA-Lyon, F-69007, Lyon, France
| | - Nathalie Massy
- Department of Pharmacology, Rouen University Hospital, F-76031, Rouen, France
| | - Jean Rouvet
- Department of Pharmacy, Cancer Centre Henri Becquerel, F-76000, Rouen, France
| | - Tony Pereira
- Department of Pharmacology, Rouen University Hospital, F-76031, Rouen, France
| | - Cristina Alexandru
- Department of Medical Oncology, Cancer Centre Henri Becquerel, F-76000, Rouen, France
| | - Chantal Hanzen
- Department of Radiation Oncology and Medical Physics, Cancer Centre Henri Becquerel, F-76000, Rouen, France
| | - Florence Basuyau
- Department of Pharmacy, Cancer Centre Henri Becquerel, F-76000, Rouen, France
| | - Olivier Langlois
- Department of Neurosurgery, Rouen University Hospital, F-76031, Rouen, France
| | - Florian Clatot
- UNIROUEN, Inserm U1245, IRON group, Institute for Research and Innovation in Biomedicine, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, Normandie Univ, F-76031, Rouen, France.,Department of Medical Oncology, Cancer Centre Henri Becquerel, F-76000, Rouen, France
| | - Isabelle Tennevet
- Department of Medical Oncology, Cancer Centre Henri Becquerel, F-76000, Rouen, France
| | - Frédéric Di Fiore
- UNIROUEN, Inserm U1245, IRON group, Institute for Research and Innovation in Biomedicine, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, Normandie Univ, F-76031, Rouen, France.,Department of Medical Oncology, Cancer Centre Henri Becquerel, F-76000, Rouen, France.,Department of Hepatogastroenterology, Rouen University Hospital, F-76031, Rouen, France
| | - Robinson Joannidès
- Department of Pharmacology, Rouen University Hospital, F-76031, Rouen, France.,UNIROUEN, Inserm U1096, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, Normandie Univ, F-76031, Rouen, France
| | - Fabien Lamoureux
- Department of Pharmacology, Rouen University Hospital, F-76031, Rouen, France.,UNIROUEN, Inserm U1096, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, Normandie Univ, F-76031, Rouen, France
| |
Collapse
|
19
|
Duflot T, Vasse M, Guillerme J, Schrapp A, Mory C, Imbert L, Djerada Z, Protais Y, Guillin O, Goetz H, Lamoureux F. Interest of adjusting urine cannabinoids to creatinine level to monitor cannabis cessation therapy in heavy smokers with psychiatric disorders. Drug Test Anal 2019; 11:1453-1459. [DOI: 10.1002/dta.2672] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Revised: 06/24/2019] [Accepted: 06/26/2019] [Indexed: 11/12/2022]
Affiliation(s)
- Thomas Duflot
- Laboratory of Pharmacokinetics, Toxicology and PharmacogenomicsRouen University Hospital 76000 Rouen France
- Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD‐VHF 76000 Rouen France
- Department of PharmacologyRouen University Hospital 76000 Rouen France
| | - Marianne Vasse
- Rouvray Psychiatric Hospital F76300 Sotteville‐Lès‐Rouen France
| | - Jennifer Guillerme
- Department of General BiochemistryRouen University Hospital Rouen France
| | - Aurélien Schrapp
- Laboratory of Pharmacokinetics, Toxicology and PharmacogenomicsRouen University Hospital 76000 Rouen France
| | - Celine Mory
- Laboratory of Pharmacokinetics, Toxicology and PharmacogenomicsRouen University Hospital 76000 Rouen France
- Department of PharmacologyRouen University Hospital 76000 Rouen France
| | - Laurent Imbert
- Laboratory of Pharmacokinetics, Toxicology and PharmacogenomicsRouen University Hospital 76000 Rouen France
- Department of PharmacologyRouen University Hospital 76000 Rouen France
| | - Zoubir Djerada
- Department of Pharmacology and ToxicologyReims University Hospital F 51092 Reims France
| | - Yves Protais
- Rouvray Psychiatric Hospital F76300 Sotteville‐Lès‐Rouen France
| | - Olivier Guillin
- Rouvray Psychiatric Hospital F76300 Sotteville‐Lès‐Rouen France
| | - Hélène Goetz
- Rouvray Psychiatric Hospital F76300 Sotteville‐Lès‐Rouen France
| | - Fabien Lamoureux
- Laboratory of Pharmacokinetics, Toxicology and PharmacogenomicsRouen University Hospital 76000 Rouen France
- Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD‐VHF 76000 Rouen France
- Department of PharmacologyRouen University Hospital 76000 Rouen France
| |
Collapse
|
20
|
Duflot T, Moreau-Grangé L, Roche C, Iacob M, Wils J, Rémy-Jouet I, Cailleux AF, Leuillier M, Renet S, Li D, Morisseau C, Lamoureux F, Richard V, Prévost G, Joannidès R, Bellien J. Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients. Cardiovasc Diabetol 2019; 18:35. [PMID: 30885203 PMCID: PMC6423843 DOI: 10.1186/s12933-019-0843-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 03/08/2019] [Indexed: 01/04/2023] Open
Abstract
Background This pathophysiological study addressed the hypothesis that soluble epoxide hydrolase (sEH), which metabolizes the vasodilator and anti-inflammatory epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acids (DHETs), contributes to conduit artery endothelial dysfunction in type 2 diabetes. Methods and results Radial artery endothelium-dependent flow-mediated dilatation in response to hand skin heating was reduced in essential hypertensive patients (n = 9) and type 2 diabetic subjects with (n = 19) or without hypertension (n = 10) compared to healthy subjects (n = 36), taking into consideration cardiovascular risk factors, flow stimulus and endothelium-independent dilatation to glyceryl trinitrate. Diabetic patients but not non-diabetic hypertensive subjects displayed elevated whole blood reactive oxygen species levels and loss of NO release during heating, assessed by measuring local plasma nitrite variation. Moreover, plasma levels of EET regioisomers increased during heating in healthy subjects, did not change in hypertensive patients and decreased in diabetic patients. Correlation analysis showed in the overall population that the less NO and EETs bioavailability increases during heating, the more flow-mediated dilatation is reduced. The expression and activity of sEH, measured in isolated peripheral blood mononuclear cells, was elevated in diabetic but not hypertensive patients, leading to increased EETs conversion to DHETs. Finally, hyperglycemic and hyperinsulinemic euglycemic clamps induced a decrease in flow-mediated dilatation in healthy subjects and this was associated with an altered EETs release during heating. Conclusions These results demonstrate that an increased EETs degradation by sEH and altered NO bioavailability are associated with conduit artery endothelial dysfunction in type 2 diabetic patients independently from their hypertensive status. The hyperinsulinemic and hyperglycemic state in these patients may contribute to these alterations. Trial registration NCT02311075. Registered December 8, 2014. Electronic supplementary material The online version of this article (10.1186/s12933-019-0843-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Thomas Duflot
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen Cedex, France.,Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France.,Laboratory of Pharmacokinetics, Toxicology and Pharmacogenetics, Rouen University Hospital, 76000, Rouen, France
| | | | - Clothilde Roche
- Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France
| | - Michèle Iacob
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen Cedex, France
| | - Julien Wils
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen Cedex, France.,Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France
| | | | | | - Matthieu Leuillier
- Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France
| | - Sylvanie Renet
- Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France
| | - Dongyang Li
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA, 95616, USA
| | - Christophe Morisseau
- Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA, 95616, USA
| | - Fabien Lamoureux
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen Cedex, France.,Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France.,Laboratory of Pharmacokinetics, Toxicology and Pharmacogenetics, Rouen University Hospital, 76000, Rouen, France
| | - Vincent Richard
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen Cedex, France.,Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France
| | - Gaëtan Prévost
- Department of Endocrinology, Rouen University Hospital, 76000, Rouen, France.,Normandie Univ, UNIROUEN, INSERM U1239, 76000, Rouen, France
| | - Robinson Joannidès
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen Cedex, France.,Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France.,Centre d'Investigation Clinique (CIC)-INSERM 1404, Rouen University Hospital, 76000, Rouen, France
| | - Jérémy Bellien
- Department of Pharmacology, Rouen University Hospital, 76000, Rouen Cedex, France. .,Normandie Univ, UNIROUEN, INSERM U1096, FHU REMOD-VHF, 76000, Rouen, France. .,Centre d'Investigation Clinique (CIC)-INSERM 1404, Rouen University Hospital, 76000, Rouen, France.
| |
Collapse
|
21
|
Darnaud L, Lamoureux F, Godet C, Pontier S, Debard A, Venisse N, Martins P, Concordet D, Gandia P. Isavuconazole Kinetic Exploration for Clinical Practice. Drugs R D 2019; 18:317-321. [PMID: 30306415 PMCID: PMC6277320 DOI: 10.1007/s40268-018-0251-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
BACKGROUND Isavuconazole is a new antifungal prodrug for the treatment of invasive aspergillosis and mucormycosis. As no clear pharmacokinetic-pharmacodynamic relationship has been established for patients, therapeutic drug monitoring is not currently required. However, as isavuconazole is a new drug, clinicians are sometimes sceptical about the exposure achieved in their patients and seek pharmacokinetic exploration. A minimal response consists of determining that the patient's pharmacokinetic profile agrees with profiles reported by Desai et al. using concentrations from the SECURE study. METHODS Based on one concentration and Desai et al.'s population-pharmacokinetic model, it is possible to estimate a patient's most likely pharmacokinetic profile. If a patient's pharmacokinetic profile is close to the profiles reported by Desai et al., therapeutic drug monitoring is not required. In contrast, when the pharmacokinetic profile differs from the Desai et al. profiles, isavuconazole concentration monitoring and pharmacokinetic profile modeling are the only methods for obtaining information on a patient's exposure and the efficacy of isavuconazole. RESULTS Four patients presented with surprising pharmacokinetic profiles, unexplained by drug interactions or cytochrome P450 3A4/5 polymorphisms. For two of them, a drug dosage adjustment was proposed and applied by clinicians, together with a check for a new pharmacokinetic profile a few days later. CONCLUSIONS Collecting one blood sample just before the first maintenance dose to make an early estimation of the patient's most likely pharmacokinetic profile is one method of identifying patients with outlier pharmacokinetic behavior.
Collapse
Affiliation(s)
- Léa Darnaud
- Laboratoire de Pharmacocinétique et Toxicologie, Institut Fédératif de Biologie, 330 Avenue Grande Bretagne, 31059, Toulouse Cedex 09, France
| | - Fabien Lamoureux
- Laboratoire de Pharmacologie, Toxicologie, Pharmacogénétique, CHU de Rouen, Rouen, France
| | - Cendrine Godet
- Service de Maladies Infectieuses, CHU de Poitiers, Poitiers, France
| | | | - Alexia Debard
- Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, Toulouse, France
| | - Nicolas Venisse
- Laboratoire de Toxicologie et Pharmacocinétique, CHU de Poitiers, Poitiers, France
| | | | | | - Peggy Gandia
- Laboratoire de Pharmacocinétique et Toxicologie, Institut Fédératif de Biologie, 330 Avenue Grande Bretagne, 31059, Toulouse Cedex 09, France. .,INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France.
| |
Collapse
|
22
|
Schrapp A, Mory C, Duflot T, Pereira T, Imbert L, Lamoureux F. The right blood collection tube for therapeutic drug monitoring and toxicology screening procedures: Standard tubes, gel or mechanical separator? Clin Chim Acta 2018; 488:196-201. [PMID: 30439354 DOI: 10.1016/j.cca.2018.10.043] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2018] [Revised: 10/31/2018] [Accepted: 10/31/2018] [Indexed: 11/28/2022]
Abstract
Stability data of toxics or drugs in gel-based or mechanical separation blood collection tubes are lacking, especially for therapeutic drug monitoring and clinical toxicology procedures. According to ISO 15189 accreditation standard, laboratories need to master the entire preanalytical process including the stability of analytes in a specific tube. Here we explored the impact of BD PST™ II and Barricor™ separator tubes on the stability of 167 therapeutic compounds and common drugs of abuse in plasma samples using LC-MS/MS. Forty drugs were significantly affected by the use of PST™ II tubes, including antidepressants (11/26), neuroleptics (9/13), cardiovascular drugs (5/26), anxiolytics and hypnotics (4/25) and some drugs of abuse (5/26). Six compounds exhibited significant reduction by the mechanical Barricor™ tubes. Ten drugs exhibited low (<85%) but non-significant recoveries due to inter-assay variability. Besides, a logP > 3.3 was determined as a cut-off value to predict a potential lack of stability in PST™ II gel tubes with an 86.4% sensitivity and a 61.4% specificity. As a consequence, determination of drugs with a logP > 3.3 should be carried out with caution in plasma samples withdrawn on PST™ II. The study showed the Barricor™ and non-gel tubes cause less drug interference and are recommended for the drugs studied.
Collapse
Affiliation(s)
- Aurélien Schrapp
- Rouen University Hospital, Department of Biochemistry, Rouen, France; Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France
| | - Céline Mory
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France
| | - Thomas Duflot
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France; Normandie University, UNIROUEN, Inserm U1096, Rouen, France
| | - Tony Pereira
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France
| | - Laurent Imbert
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France
| | - Fabien Lamoureux
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France; Normandie University, UNIROUEN, Inserm U1096, Rouen, France.
| |
Collapse
|
23
|
Duflot T, Marie-Cardine A, Verstuyft C, Filhon B, Pereira T, Massy-Guillemant N, Joannidès R, Bellien J, Lamoureux F. Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases. Fundam Clin Pharmacol 2018; 32:337-342. [PMID: 29319893 DOI: 10.1111/fcp.12345] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Revised: 01/02/2018] [Accepted: 01/04/2018] [Indexed: 12/16/2022]
Abstract
Ifosfamide (IFA) is a potent alkylating antitumoral agent, but its use is limited by neurological side effects. IFA is a racemic mixture of two enantiomeric forms, R-IFA and S-IFA with a stereoselective metabolism by CYP3A4 and CYP2B6, leading either to bioactive or to toxic pathways. In three consecutive cases of pediatric patients who exhibited IFA-induced encephalopathy (IIE), genotyping of clinically relevant single-nucleotide polymorphisms associated with decreased CYP3A4 and CYP2B6 activities was performed. Genetic investigations revealed the presence of CYP2B6 rs4803419 (C>T) in one patient while the two others carried the CYP2B6*6 allelic variant. All patients carried CYP3A4 wild-type genotype (CYP3A4*1/*1). Because CYP2B6-deficient alleles may be responsible for an increased conversion of S-IFA into neurotoxic metabolites, screening for CYP2B6 polymorphisms may help to avoid IIE and improve clinical outcomes.
Collapse
Affiliation(s)
- Thomas Duflot
- Department of Pharmacology, Rouen University Hospital, 1 rue de Germont, F 76000, Rouen, France.,Normandie Univ, UNIROUEN, Inserm U1096, Rouen University, 22 boulevard Gambetta, F 76000, Rouen, France
| | - Aude Marie-Cardine
- Department of Pediatric Hematology and Oncology, Rouen University Hospital, 1 rue de Germont, F 76000, Rouen, France
| | - Céline Verstuyft
- Service de Genetique moleculaire, Pharmacogenetique et Hormonologie, CHU Bicêtre, AP-HP, 78 rue du Général Leclerc, 94275, Le Kremlin Bicêtre Cedex, France
| | - Bruno Filhon
- Department of Pediatric Hematology and Oncology, Rouen University Hospital, 1 rue de Germont, F 76000, Rouen, France
| | - Tony Pereira
- Department of Pharmacology, Rouen University Hospital, 1 rue de Germont, F 76000, Rouen, France
| | | | - Robinson Joannidès
- Department of Pharmacology, Rouen University Hospital, 1 rue de Germont, F 76000, Rouen, France.,Normandie Univ, UNIROUEN, Inserm U1096, Rouen University, 22 boulevard Gambetta, F 76000, Rouen, France
| | - Jérémy Bellien
- Department of Pharmacology, Rouen University Hospital, 1 rue de Germont, F 76000, Rouen, France.,Normandie Univ, UNIROUEN, Inserm U1096, Rouen University, 22 boulevard Gambetta, F 76000, Rouen, France
| | - Fabien Lamoureux
- Department of Pharmacology, Rouen University Hospital, 1 rue de Germont, F 76000, Rouen, France.,Normandie Univ, UNIROUEN, Inserm U1096, Rouen University, 22 boulevard Gambetta, F 76000, Rouen, France
| |
Collapse
|
24
|
Duflot T, Schrapp A, Bellien J, Lamoureux F. Impact of CYP3A4 Genotype on Voriconazole Exposure. Clin Pharmacol Ther 2017; 103:185-186. [PMID: 28786228 DOI: 10.1002/cpt.809] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Revised: 06/09/2017] [Accepted: 06/19/2017] [Indexed: 11/07/2022]
Affiliation(s)
- Thomas Duflot
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France.,Normandie University, UNIROUEN, Inserm U1096, Rouen, France
| | - Aurélien Schrapp
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France
| | - Jérémy Bellien
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France.,Normandie University, UNIROUEN, Inserm U1096, Rouen, France
| | - Fabien Lamoureux
- Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France.,Normandie University, UNIROUEN, Inserm U1096, Rouen, France
| |
Collapse
|
25
|
Lamoureux F, Duflot T. Pharmacogénétique en cardiovasculaire : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx). Therapie 2017; 72:245-255. [DOI: 10.1016/j.therap.2016.09.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 09/02/2016] [Indexed: 02/03/2023]
|
26
|
Lamoureux F, Duflot T. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx). Therapie 2017; 72:257-267. [PMID: 28237404 DOI: 10.1016/j.therap.2016.09.017] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 09/02/2016] [Indexed: 10/20/2022]
Abstract
The use of genomic markers to predict drug response and effectiveness has the potential to improve healthcare by increasing drug efficacy and minimizing adverse effects. Polymorphisms associated with inter-individual variability in drug metabolism, transport, or pharmacodynamics of major cardiovascular drugs have been identified. These include single nucleotide polymorphisms (SNP) affecting clinical outcomes in patients receiving antiplatelet agents, oral anticoagulants and statins. Based on clinical evidence supporting genetic testing in the management of cardiovascular diseases using these drug classes, this short review presents clinical guidance regarding current pharmacogenetics implementation in routine medical practice.
Collapse
Affiliation(s)
- Fabien Lamoureux
- Service de pharmacologie, laboratoire de pharmacologie-toxicologie et pharmacogénétique, centre hospitalier universitaire, 76031 Rouen, France; Inserm unité 1096, pharmacologie des dysfonctionnements endothéliaux et myocardiques, faculté de médecine et de pharmacie, université de Rouen, 76000 Rouen, France.
| | - Thomas Duflot
- Service de pharmacologie, laboratoire de pharmacologie-toxicologie et pharmacogénétique, centre hospitalier universitaire, 76031 Rouen, France; Inserm unité 1096, pharmacologie des dysfonctionnements endothéliaux et myocardiques, faculté de médecine et de pharmacie, université de Rouen, 76000 Rouen, France
| | | |
Collapse
|
27
|
Ngo S, Chamouni P, Lenain P, Lamoureux F, Levesque H. Polyglobulie secondaire : devrait-on penser au cannabis ? Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
Raymond J, Riachi G, Goria O, Montialoux H, Leporrier J, Mourez T, Lamoureux F, Mannessier G, Donnadieu N. HEP-10 - Bilan d’une année de RCP hépatite C. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30387-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
David M, Leprêtre S, Loeb A, Lamoureux F, Grenet J, Perdrix A, Bastard C. BU-24 - Évaluation rétrospective de la prophylaxie antifongique par posaconazole en hématologie. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30348-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Lamoureux F, Duflot T, Woillard JB, Metsu D, Pereira T, Compagnon P, Morisse-Pradier H, El Kholy M, Thiberville L, Stojanova J, Thuillez C. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents 2016; 47:124-31. [DOI: 10.1016/j.ijantimicag.2015.12.003] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Revised: 11/10/2015] [Accepted: 12/01/2015] [Indexed: 12/01/2022]
|
31
|
Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A. Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. Oncogenesis 2014; 3:e115. [PMID: 25133482 PMCID: PMC5189960 DOI: 10.1038/oncsis.2014.30] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2014] [Revised: 05/22/2014] [Accepted: 06/03/2014] [Indexed: 12/27/2022] Open
Abstract
Castrate-resistant prostate cancer (CRPC) progression is a complex process by which prostate cells acquire the ability to survive and proliferate in the absence or under very low levels of androgens. Most CRPC tumors continue to express the androgen receptor (AR) as well as androgen-responsive genes owing to reactivation of AR. Protein tyrosine kinases have been implicated in supporting AR activation under castrate conditions. Here we report that Lyn tyrosine kinase expression is upregulated in CRPC human specimens compared with hormone naive or normal tissue. Lyn overexpression enhanced AR transcriptional activity both in vitro and in vivo and accelerated CRPC. Reciprocally, specific targeting of Lyn resulted in a decrease of AR transcriptional activity in vitro and in vivo and prolonged time to castration. Mechanistically, we found that targeting Lyn kinase induces AR dissociation from the molecular chaperone Hsp90, leading to its ubiquitination and proteasomal degradation. This work indicates a novel mechanism of regulation of AR stability and transcriptional activity by Lyn and justifies further investigation of the Lyn tyrosine kinase as a therapeutic target for the treatment of CRPC.
Collapse
Affiliation(s)
- A Zardan
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - K M Nip
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - D Thaper
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - P Toren
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - S Vahid
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - E Beraldi
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - L Fazli
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - F Lamoureux
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - K M Gust
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - M E Cox
- 1] The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - J L Bishop
- The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - A Zoubeidi
- 1] The Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
32
|
Lamoureux F, Dubos C, Dulaurent S, Gaulier JM, Compagnon P. O47: Analyse d’une série de cas d’exposition au cannabis chez des nourrissons et des jeunes enfants : intérêt des prélèvements capillaires. Toxicologie Analytique et Clinique 2014. [DOI: 10.1016/s2352-0078(14)70055-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Camus V, Thibault ML, David M, Gargala G, Compagnon P, Lamoureux F, Girault C, Michot JB, Stamatoullas A, Lanic H, Jardin F, Lenain P, Tilly H, Leprêtre S. Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review. Mycopathologia 2014; 177:319-24. [PMID: 24748454 DOI: 10.1007/s11046-014-9746-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Accepted: 04/08/2014] [Indexed: 10/25/2022]
Abstract
Invasive Geotrichum clavatum fungal infections are extremely rare and unusual, occurring nearly exclusively in patients experiencing prolonged neutropenia during the treatment for acute myeloid leukaemia. Several groups of cases of fatal G. clavatum infection were reported in France between 2011 and 2012, but the ecological niche has not yet been identified. We report a case of a 32-year-old patient with acute myeloid leukaemia who developed G. clavatum sepsis with primary peritonitis, hepatic nodular lesions, and multivisceral failure during aplasia after induction followed by salvage chemotherapy. He was treated with voriconazole and is still alive 1 year after with controlled disease. We then discuss the epidemiological, clinical, and therapeutic features of these serious fungal infections compared to the published data.
Collapse
Affiliation(s)
- Vincent Camus
- Department of Hematology, Centre Henri Becquerel, rue d'Amiens, 76038, Rouen, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Duflot T, Roche C, Lamoureux F, Guerrot D, Bellien J. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. Expert Opin Drug Discov 2014; 9:229-43. [PMID: 24490654 DOI: 10.1517/17460441.2014.881354] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Cardiovascular diseases are a leading cause of death in developed countries. Increasing evidence shows that the alteration in the normal functions of the vascular endothelium plays a major role in the development of cardiovascular diseases. However, specific agents designed to prevent endothelial dysfunction and related cardiovascular complications are still lacking. One emerging strategy is to increase the bioavailability of epoxyeicosatrienoic acids (EETs), synthesized by cytochrome P450 epoxygenases from arachidonic acid. EETs are endothelium-derived hyperpolarising and relaxing factors and display attractive anti-inflammatory and metabolic properties. Genetic polymorphism studies in humans, and experiments in animal models of diseases, have identified soluble epoxide hydrolase (sEH), the major enzyme involved in EET degradation, as a potential pharmacological target. AREAS COVERED This review presents EET pathway and its functions and summarises the data supporting the development of sEH inhibitors for the treatment of cardiovascular and metabolic diseases. Furthermore, the authors present the different chemical families of sEH inhibitors developed and their effects in animal models of cardiovascular and metabolic diseases. EXPERT OPINION Several generations of sEH inhibitors have now been designed to treat endothelial dysfunction and cardiovascular complications for a variety of diseases. The safety of these drugs remains to be carefully investigated, particularly in relation to carcinogenesis. The increasing knowledge of the biological role of each of the EET isomers and of their metabolites may improve their pharmacological profile. This, in turn, could potentially lead to the identification of new pharmacological agents that achieve the cellular effects needed without the deleterious side effects.
Collapse
Affiliation(s)
- Thomas Duflot
- Rouen University Hospital, Department of Pharmacology , Rouen , France
| | | | | | | | | |
Collapse
|
35
|
El Kholy M, Morisse Pradier H, Compagnon P, Lamoureux F, Gargala G, Dominique S, Chabaud A, Muir JF, Thiberville L. Suivi thérapeutique pharmacologique du voriconazole chez les patients présentant une pathologie aspergillaire pulmonaire non neutropénique. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
Lamoureux F, Mestre E, Essig M, Sauvage FL, Marquet P, Gastinel LN. Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus. J Proteomics 2011; 75:677-94. [PMID: 21964257 DOI: 10.1016/j.jprot.2011.09.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2011] [Revised: 08/25/2011] [Accepted: 09/08/2011] [Indexed: 11/19/2022]
Abstract
The calcineurin-inhibitors (CNIs) cyclosporine (CsA) and tacrolimus (TAC) remain the pillars of modern immunosuppression regimens used in solid organ transplantation. Nephrotoxicity is an adverse effect that limits their successful use. The precise molecular mechanisms underlying this nephrotoxicity remain unclear. Using SILAC together with LC-MALDI-TOF/TOF, we investigated the CNIs-induced proteomic perturbations in renal cells. Among the 495 proteins quantifiable in both forward and reverse SILAC, 69 displayed CsA-induced perturbations: proteins involved in ER-stress/protein folding, apoptosis, metabolism/transport or cytoskeleton pathways were up-regulated, while cyclophilin B as well as nuclear and RNA-processing proteins were down-regulated. Co-administration of CsA with the antioxidant N-acetylcysteine significantly decreased lipid peroxidation and also partially corrected the CsA-induced unfolded protein response. TAC toxicity profile was apparently different from that of CsA, especially without perturbation of cyclophilins A and B, up-regulation of ER-chaperones nor down-regulation of a number of nuclear proteins. These results provide a new insight and are consistent with recent data regarding the molecular mechanisms of CNIs-induced nephrotoxicity. Our findings offer new directions for future research aiming to identify specific biomarkers of CsA nephrotoxicity.
Collapse
|
37
|
Thomas C, Lamoureux F, Crafter C, Davies B, Zoubeidi A, Gleave M. UP-02.098 The Novel AKT-Inhibitor AZD5363 Abrogates Androgen-Receptor Signaling and Delays Hormone-Sensitive and Castration-Resistant Prostate Cancer Progression in vivo. Urology 2011. [DOI: 10.1016/j.urology.2011.07.916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Thomas C, Wafa L, Lamoureux F, Fazli L, Rennie P, Gleave M. MP-03.04 The Combination Treatment of Bicalutamide Plus Carbidopa Significantly Enhances the in vivo Antitumor Activity on LNCaP Castration-resistant Prostate Cancer Xenograft Tumors Compared To Single Use of Each Drug. Urology 2011. [DOI: 10.1016/j.urology.2011.07.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
39
|
Lamoureux F, Picard N, Boussera B, Sauvage FL, Marquet P. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. Fundam Clin Pharmacol 2011; 26:463-72. [DOI: 10.1111/j.1472-8206.2011.00957.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Lamoureux F, Yin M, Zoubeidi A, Gleave ME. CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Picard N, Levoir L, Lamoureux F, Yee SW, Giacomini KM, Marquet P. Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica 2011; 41:752-7. [DOI: 10.3109/00498254.2011.573882] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
42
|
Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta Rev Cancer 2009; 1805:17-24. [PMID: 19733222 DOI: 10.1016/j.bbcan.2009.08.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2009] [Revised: 08/24/2009] [Accepted: 08/28/2009] [Indexed: 10/20/2022]
Abstract
Tumor development in bone is often associated with fractures, bone loss and bone pain, and improvement is still needed in therapeutic approaches. Bone tumors are related to the existence of a vicious cycle between bone resorption and tumor proliferation in which the molecular triad osteoprotegerin (OPG)/receptor activator of NF-kappaB (RANK)/RANK ligand (RANKL) plays a pivotal role. RANKL, a member of the TNF superfamily, is one of the main inducers of bone resorption. Its soluble receptor OPG represents a promising therapeutic candidate as it prevents bone lesions and inhibits associated tumor growth. However, its therapeutic use in bone tumors remains controversial due to its ability to bind and inhibit another member of the TNF superfamily, TNF related apoptosis inducing ligand (TRAIL), which is a potent inducer of tumor cell apoptosis. Through its heparin binding domain, OPG is also able to bind proteoglycans present in the bone matrix. This paper is an overview of the involvement of the micro-environment, as represented by the balance of RANKL/TRAIL and the presence of proteoglycans in the regulation of OPG biological activity in bone tumors.
Collapse
Affiliation(s)
- F Lamoureux
- INSERM U957-EA 3822, Nantes Atlantique Universités, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Faculté de Médecine, Université de Nantes, 1 rue Gaston Veil, Nantes, France
| | | | | | | | | | | |
Collapse
|
43
|
Arlicot N, Rochefort GY, Schlecht D, Lamoureux F, Marchand S, Antier D. Stability of antibiotics in portable pumps used for bronchial superinfection: guidelines for prescribers. Pediatrics 2007; 120:1255-9. [PMID: 18055674 DOI: 10.1542/peds.2007-0630] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
OBJECTIVES The aims of this study were (1) to collect data on the stability of antibiotics in portable pumps for the treatment of bronchial superinfection in patients with cystic fibrosis and (2) to provide guidelines for prescribers. METHODS The stability over 72 hours, in portable pumps stored at 35 degrees C, of piperacillin plus tazobactam, ticarcillin plus clavulanic acid, cefsulodin, cefepime, and aztreonam was checked at 3 different concentrations. Stability was assessed through visual examination, pH measurements, and direct measurements of drug concentrations by using high-performance liquid chromatography. All parameters were measured at time 0, time 0 plus 24 hours, and time 0 plus 72 hours. RESULTS Degradation rates for penicillin plus beta-lactamase inhibitor combinations remained <10% at time 0 plus 24 hours for all drugs, but the rate for piperacillin reached 12% for the highest concentration tested. The cephalosporins cefepime and cefsulodin had significant respective degradation rates of 18% and 28% at time 0 plus 24 hours and 60% and 68.5% at time 0 plus 72 hours, which were linked to the storage temperature. Aztreonam seemed to be stable over 72 hours. CONCLUSIONS This work provides data on drug stability that were lacking, allowing recommendations for physicians to optimize the safety and efficacy of antibiotic treatment of patients with cystic fibrosis. Piperacillin plus tazobactam and ticarcillin plus clavulanic acid infusions must be limited to 24 hours, and patients receiving cefepime or cefsulodin must wear a cold pack close to the ambulatory drug-delivery device during the infusion.
Collapse
Affiliation(s)
- Nicolas Arlicot
- Department of Pharmacy, University Hospital of Tours, 2 Blvd Tonnellé, 37044 Tours Cedex, France
| | | | | | | | | | | |
Collapse
|
44
|
Abstract
1997 saw the identification of a novel set of proteins within the tumor necrosis factor (TNF)/TNF receptor families that are required for the control of bone remodeling. Therefore, these receptors, receptor activator of nuclear factor kappa B (RANK), osteoprotegerin (OPG) and their ligand RANK ligand (RANKL) became the critical molecular triad controlling osteoclastogenesis and pathophysiologic bone remodeling. However, the establishment of the corresponding knock-out and transgenic mice revealed unexpected results, most particularly, the involvement of these factors in the vascular system and immunity. Thus, the OPG/RANK/RANKL molecular triad appears to be associated with vascular calcifications and plays a pivotal function in the development of the immune system through dendritic cells. OPG/RANK/RANKL thus constitute a molecular bridge spanning bone metabolism, vascular biology and immunity. This review summarizes recent knowledge of OPG/RANK/RANKL interactions and activities as well as the current evidence for their participation in osteoimmunology and vascular diseases. In fine, the targeting of the OPG/RANK/RANKL axis as novel therapeutic approaches will be discussed.
Collapse
Affiliation(s)
- M Baud'huin
- Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822, Université de Nantes, Nantes Atlantique Universités, F-44035, Nantes, France
| | | | | | | | | |
Collapse
|
45
|
De Calbiac P, Lamoureux F, Pourrat X, Bretault L, Marchand S, Grassin J, Antier D. [Treatment of bronchial superinfections: data related to stability of antibiotics in portable pumps]. Therapie 2006; 61:139-44. [PMID: 16886707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
INTRODUCTION Given many data about the stability of antibiotics in portable pump (elastomer) are lacking, this study was designed to make a point about available data and to evaluate the stability of antibiotics when exposed to temperature within 35 degrees C (average temperature measured in real conditions of use). MATERIAL AND METHODS First, to collect information about the stability of antibiotics in portable pump and to confront them with the local antibiotics protocols dedicated to the treatment of bronchial superinfection in patients with cystic fibrosis; second, to evaluate the stability of piperacillin associated with tazobactam at 35 degrees C. RESULTS While measured concentrations in tazobactam did not show significant variation during the study, piperacillin measurements showed a major reduction of concentration (up to 33%), both time and concentration related to. DISCUSSION Such information must be pointed out to prescribers and patients to ensure a cold accumulator is placed in the pump carrying-bag and to limit the duration of infusion to 24 h with a single pump. CONCLUSION This experimental program will keep on going with the stability study of both ticarcillin and cefsulodin in portable pump.
Collapse
Affiliation(s)
- Pascale De Calbiac
- Laboratoire d'analyses et de contrôle qualité, Pharmacie Logipôle Trousseau, CHU de Tours, Tours, France
| | | | | | | | | | | | | |
Collapse
|
46
|
Calbiac PD, Lamoureux F, Pourrat X, Bretault L, Marchand S, Grassin J, Antier D. Traitement des surinfections bronchiques: stabilité des antibiotiques dans les diffuseurs portatifs. Therapie 2006; 61:139-44. [DOI: 10.2515/therapie:2006031] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2005] [Accepted: 03/06/2006] [Indexed: 11/20/2022]
|
47
|
Soucy JP, McNamara D, Mohr G, Lamoureux F, Lamoureux J, Danais S. Evaluation of vasospasm secondary to subarachnoid hemorrhage with technetium-99m-hexamethyl-propyleneamine oxime (HM-PAO) tomoscintigraphy. J Nucl Med 1990; 31:972-7. [PMID: 2348242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Vasospasm of intracranial vessels is difficult to diagnose on clinical ground alone. Still, a clear diagnosis is important because it can impact on surgical timing; and also because it can help evaluate new treatments. Fifteen patients with sub-arachnoid hemorrhage secondary to aneurysm rupture were submitted to a total of 26 tomographic technetium-99m-hexamethyl-propyleneamine oxime (99mTc-HM-PAO) brain examinations that were correlated with temporally close (generally less than 24 hr) angiography or transmission computed tomography (TCT). Nine of 10 angiographically confirmed episodes of spasm and 6 of 6 infarcts seen on angiography or TCT were correctly diagnosed with 99mTc-HM-PAO. One normal scintigraphic exam was angiographically doubtful, one positive 99mTc-HM-PAO study was normal on angiography (sub-radiologic spasm?), one technically poor scintigraphy was positive for spasm on angiograms, and eight exams were normal for spasm with all modalities. We had agreement between tests in 23 of 26 series of exams (88%) obtained in 15 patients. We think that 99mTc-HM-PAO tomography should be useful for the evaluation of patients with suspected vasospasm.
Collapse
Affiliation(s)
- J P Soucy
- Department of Nuclear Medicine, Notre-Dame Hospital, Montreal, Canada
| | | | | | | | | | | |
Collapse
|
48
|
Morais J, Soucy JP, Sestier F, Lamoureux F, Lamoureux J, Danais S. Dipyridamole testing compared to exercise stress for thallium-201 imaging in patients with left bundle branch block. Can J Cardiol 1990; 6:5-8. [PMID: 2310995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Because of numerous reports of false positive results with thallium-201 (Tl-201) stress testing in patients with left bundle branch block, the authors decided to evaluate another mode of coronary vasodilatation, dipyridamole, for the diagnosis of coronary atheromatosis. Nine patients were prospectively studied with stress and dipyridamole Tl-201 scintigraphy; both tests were performed within three to 79 days of one another. Five of the patients also had coronary angiograms (four within one year, one five years earlier). Four of the patients had normal results with both tests (two normal angiograms, two not performed); two had reversible septal defects with stress-induced coronary vasodilatation but normal dipyridamole studies (only one had an angiogram, which was normal); one patient had a fully reversible septal defect with stress and a fixed defect with dipyridamole (normal angiogram); one had a partially reversible septal stress defect which was fixed with dipyridamole; and one had a normal stress study but a reversible septal defect with dipyridamole (an angiogram performed five years earlier showed 30 to 40% stenosis of the anterior descending artery). Because it seems that dipyridamole produces fewer false positive results, it should be used instead of stress testing to induce coronary vasodilatation in patients with left bundle branch block.
Collapse
Affiliation(s)
- J Morais
- Department of Nuclear Medicine, Notre-Dame Hospital, Montreal, Quebec
| | | | | | | | | | | |
Collapse
|
49
|
Rendak I, Gagnon RM, Lamoureux F. Spontaneous resolution of severe right ventricular dysfunction in right ventricular infarction: documentation by radionuclide studies. Can J Cardiol 1985; 1:306-9. [PMID: 3842094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
A case of inferior myocardial infarction complicated by severe arrhythmias and right heart failure is presented. Radionuclide studies performed near the acute phase and one month later illustrate the reversibility of right heart dysfunction caused by infarction. Signs of right ventricular involvement in acute inferior myocardial infarction are noted in about 40% of cardiac blood-pool studies: right ventricular dilatation with a significantly decreased ejection fraction, and ventricular wall motion abnormalities. Follow-up studies in the recovery period show good recovery of right ventricular function.
Collapse
|
50
|
Lamoureux F. [Nuclear medicine]. Union Med Can 1983; 112:893-900. [PMID: 6659168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|